Loading organizations...
Based in Stockholm, Sweden, AnaCardio is a clinical-stage biopharmaceutical company developing novel therapeutics to treat heart failure. The organization focuses on creating a safe contractile agent that targets the ghrelin receptor to strengthen heart muscle contractility without the harmful side effects of conventional therapies. Operating with a team of nine employees, the enterprise has raised €13.7 million in Series A funding to advance its clinical pipeline. AnaCardio is backed by notable investors including Novo Holdings, Flerie Invest, and Industrifonden, and maintains a strategic licensing agreement with Helsinn. The company recently reported strong Phase 2a topline results for its lead drug candidate, AC01, paving the way for Phase 2b trials and securing a United States patent. AnaCardio was founded in 2019 by Professor Lars Lund based on his cardiovascular research conducted at the Karolinska Institutet.
AnaCardio has raised $35.7M across 3 funding rounds.
AnaCardio has raised $35.7M in total across 3 funding rounds.
AnaCardio has raised $35.7M across 3 funding rounds. Most recently, it raised $18.0M Series A in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2025 | $18M Series A | Novo Holdings, Pureos Bioventures, Sound Bioventures | Adjuvant Capital, Kurma Partners, Pureos Bioventures | Announced |
| Sep 9, 2022 | $14.1M Series A | Mark Quick, Industrifonden | — | Announced |
| Feb 3, 2022 | $3.6M Venture Round | — | — | Announced |
AnaCardio has raised $35.7M in total across 3 funding rounds.
AnaCardio's investors include Novo Holdings, Pureos Bioventures, Sound Bioventures, Adjuvant Capital, Kurma Partners, Mark Quick, Industrifonden.
AnaCardio is a Stockholm-based clinical-stage biopharmaceutical company developing novel drugs to treat heart failure by strengthening the heart muscle safely through a unique contractile mechanism. Its lead drug candidate, AC01, targets heart failure with reduced ejection fraction (HFrEF) by enhancing cardiac contractility without the harmful side effects typical of conventional therapies. The company serves heart failure patients and aims to improve their organ function, quality of life, and reduce hospitalization and mortality risks. AnaCardio has demonstrated clinical progress, including strong Phase 2a topline results announced in December 2025, positioning it for rapid advancement in clinical development[1][3][5].
Founded on groundbreaking research from Karolinska Institutet, AnaCardio’s origin traces back to Professor Lars Lund, a renowned heart failure expert whose decade-long research identified the novel contractile mechanism. The company operationally launched in 2021 with a seed round and licensing agreement with Helsinn, leveraging preclinical and early clinical data. CEO Patrik Strömberg, with over 20 years of pharmaceutical industry experience, leads a lean, expert team closely collaborating with Karolinska Institutet and supported by innovation hubs like KI Innovations[1][4].
AnaCardio rides the trend of precision biopharmaceutical innovation targeting chronic diseases with high unmet medical needs, specifically heart failure—a major global health burden with limited curative options. The timing is critical as heart failure prevalence rises with aging populations, and current treatments often have significant side effects or limited efficacy. AnaCardio’s approach aligns with the growing focus on safer, mechanism-based therapies that improve patient outcomes and reduce healthcare costs. By advancing a novel drug class, AnaCardio influences the cardiovascular drug development ecosystem and exemplifies successful translation of academic research into clinical-stage biotech innovation[1][4].
AnaCardio is poised to advance rapidly through clinical development, aiming for a market-ready drug shortly after 2030. Future trends shaping its journey include increasing demand for heart failure therapies that balance efficacy and safety, and the expansion of precision medicine approaches in cardiology. Its influence may grow as it validates a new drug class, potentially reshaping heart failure treatment paradigms and inspiring further innovation in contractile agents. Continued collaboration with academic institutions and strategic partnerships will be key to scaling its impact in the global biopharmaceutical landscape[5][1].
